Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

Exclusion Criteria

• •1. Age \<18 years
• •2. Unable to give informed consent
• •3. Pregnant women or breast-feeding mothers
• •4. Previous transfusion reaction or other contraindication to a plasma transfusion
• •5. Known hypersensitivity to camostat mesylate and/or severe pancreatitis
• •6. Volume stress due to CP administration would be intolerable
• •7. Known IgA deficiency
• •8. Life expectancy \< 6 months
• •9. Duration SARS-CoV-2 typical symptoms \> 3 days
• •10. SARS-CoV-2 PCR detection older than 3 days
• •12. Previously or currently hospitalized due to SARS-CoV-2
• •13. Previous antiviral therapy for SARS-CoV-2
• •14. alanine aminotransferase (ALT) or aspartate transferase (AST) \> 5 times upper limit of normal (ULN) at screening
• •15. Liver cirrhosis \> Child A (patients with Child B/C cirrhosis are excluded from the trial)
• •16. Chronic kidney disease with GFR \< 30 ml/min
• •17. Concurrent or planned anticancer treatment during trial period
• •18. Accommodation in an institution due to legal orders (§40(4) AMG).
• •19. Any psycho-social condition hampering compliance with the study protocol.
• •20. Evidence of current drug or alcohol abuse.
• •21. Use of other investigational treatment within 5 half-lives of enrollment is prohibited
• •22. Previous use of convalescent plasma for COVID-19
• •23. Concomitant proven influenza A infection
• •24. Patients with organ or bone marrow transplant in the three months prior to Screening Visit